Search results
Search for "theragnostic" in Full Text gives 6 result(s) in Beilstein Journal of Nanotechnology.
Therapeutic effect of F127-folate@PLGA/CHL/IR780 nanoparticles on folate receptor-expressing cancer cells
Beilstein J. Nanotechnol. 2024, 15, 954–964, doi:10.3762/bjnano.15.78
- Minh City, 700000, Vietnam Institute of Chemical Technology – VAST, Ho Chi Minh City, 700000, Vietnam Institute of Applied Technology and Sustainable Development, Nguyen Tat Thanh University, Ho Chi Minh City 700000, Vietnam 10.3762/bjnano.15.78 Abstract Theragnostic platforms, which integrate
- ). Additionally, the F127-folate@PLGA/CHL/IR780 nanoparticles exhibited a lower IC50 value against cancer cells than non-targeted F127@PLGA/CHL/IR780 nanoparticles. These findings suggest that the developed F127-folate@PLGA/CHL/IR780 nanoparticles hold promise as a theragnostic system for targeted cancer therapy
- and diagnosis, leveraging the advantages of PLGA, folate targeting, and the integration of therapeutic and imaging agents. Keywords: cancer; chlorambucil; drug carrier; IR780; PLGA nanoparticle; theragnostic; Introduction Poly(ᴅ,ʟ-lactic-co-glycolic acid) (PLGA), a copolymer of poly(lactic acid
Cholesterol nanoarchaeosomes for alendronate targeted delivery as an anti-endothelial dysfunction agent
Beilstein J. Nanotechnol. 2024, 15, 517–534, doi:10.3762/bjnano.15.46
- therapeutic, diagnostic, or theragnostic applications to pathological macrophages and endothelia is of major pharmaceutical interest [21]. The vascular endothelium can be actively targeted with nanomedicines of high structural sophistication [22][23], which are, however, difficult to fit within the
Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics
Beilstein J. Nanotechnol. 2024, 15, 180–189, doi:10.3762/bjnano.15.17
- nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform. Therefore, formulating a nanocarrier system that could serve as theragnostic agent by using simple techniques would be an advantage during production. In this project, we aimed to develop a
- of these systems to serve as medication and imaging agent carriers for cancer treatment and diagnostics, respectively. Keywords: cancer; chlorambucil; F127-folate; IR780; iron oxide nanoparticles; PLGA; theragnostics; Introduction Theragnostic nanoparticles (NPs) are a diagnostic and therapeutic
- urinary obstruction [14]. In another study, PLGA SPIONs could transport chemotherapeutic agents for cancer treatment and diagnosis [15]. Therefore, the combination of PLGA and SPIONs promises a useful theragnostic system in our study. In addition to the encapsulation of SPIONs in PLGA employed for
The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors
Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31
Mismatch detection in DNA monolayers by atomic force microscopy and electrochemical impedance spectroscopy
Beilstein J. Nanotechnol. 2016, 7, 220–227, doi:10.3762/bjnano.7.20
- experimental data. Acknowledgements This work was supported by a FIRB 2011 grant “Nanotechnological approaches toward tumor theragnostic” (P.P., E.A., M.D.N.N. and L.C.), a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) to L.C. and P.C. (AIRC 5 per mille 2011, no. 12214), and European
Caveolin-1 and CDC42 mediated endocytosis of silica-coated iron oxide nanoparticles in HeLa cells
Beilstein J. Nanotechnol. 2015, 6, 167–176, doi:10.3762/bjnano.6.16
- applications. Nowadays they are already in use in magnetic resonance imaging [6][7][8] and the thermotherapy of tumors [9][10][11]. Also for the investigation of applications in theragnostic and drug delivery iron oxide nanoparticles are promising tools for the future [12][13][14][15][16][17][18]. Despite the
Other Beilstein-Institut Open Science Activities
